Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

(2011) Peter Hillmen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Update on Therapy of Chronic Lymphocytic Leukemia

(2011) John G. Gribben et al.   JOURNAL OF CLINICAL ONCOLOGY

High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment

(2011) A. C. Logan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Human peripheral blood B-cell compartments: A crossroad in B-cell traffic

(2010) M. Perez-Andres et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience

(2009) P. Abrisqueta et al.   BLOOD

Flow cytometry APC-tandem dyes are degraded through a cell-dependent mechanism

(2009) Christine Le Roy et al.   CYTOMETRY PART A

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia

(2009) Francesc Bosch et al.   JOURNAL OF CLINICAL ONCOLOGY

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

(2009) S Böttcher et al.   LEUKEMIA

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

(2008) C. S. Tam et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication

(2008) F. Bosch et al.   CLINICAL CANCER RESEARCH

A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders

(2008) C.E. Pedreira et al.   CYTOMETRY PART A

Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations

(2008) S. Bottcher et al.   HAEMATOLOGICA